Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Otsuka Pharmaceutical and Bristol-Myers Squibb have announced that Abilify has received expanded indications in bipolar I disorder and schizophrenia.
Subscribe to our email newsletter
Abilify is now indicated for the maintenance treatment of manic and mixed episodes associated with bipolar I disorder with or without psychotic features in pediatric patients (aged 10-17) and maintenance treatment of schizophrenia in adolescents (aged 13-17).
In addition, Abilify is also granted an indication for adjunctive therapy to either lithium or valproate for the acute treatment of manic and mixed episodes associated with bipolar I disorder with or without psychotic features in pediatric patients (aged 10-17).
Elliott Sigal, executive vice president, chief scientific officer and president, R&D, Bristol-Myers Squibb, said: “Expanding the clinical uses of an important therapy such as Abilify gives caregivers and pediatric patients with bipolar I disorder or schizophrenia, a new treatment option in their fight against serious disease.”